5. Molecular Therapies for Iinflammatory and Autoimmune Diseases: Ongoing Clinical Trials and Future Prospects
6. Virtual Screening and Profiling
13:45
Session Chair
Sheng DING (THE SCRIPPS RESEARCH INSTITUTE, La Jolla, United States)
13:50
Cardiovascular Derivatives of Human Pluripotent Stem Cells: Chemical Modulation and Use in Drug Discovery, Development, and Toxicology
Christine MUMMERY (LEIDEN UNIVERSITY MEDICAL CENTER, Leiden, The Netherlands)
14:30
Development of Small Molecule Therapeutics for Treating Endogenous Cells for Repair and Regeneration
Francine FAROUZ (FATE THERAPEUTICS, La Jolla, United States)
15:10
Chemical Modulation of Stem Cells
Ravi JAGASIA (HOFFMANN - LA ROCHE, Basel, Switzerland)
13:45
Session Chair
Sylviane MULLER (IBMC-CNRS, Strasbourg, France)
13:50
Molecular Therapies for Inflammatory and Autoimmune Diseases - Focus on Systemic Lupus Erythematosus
Sylviane MULLER (IBMC-CNRS, Strasbourg, France)
14:30
Generation and Development of a Series of MAPKAPK5 Inhibitors for the Treatment of Rheumatoid Arthritis
Martin ANDREWS (GALAPAGOS NV, Mechelen, Belgium)
14:50
Discovery And Optimization Of Highly Selective Btk Inhibitors That Bind To An Inactive Enzyme Conformation And Are Efficacious In Animal Models Of Arthritis And Lupus
Kevin CURRIE (CGI PHARMACEUTICALS, INC., Branford, United States)
15:10
Optimisation Of The Diaminopyrimidine Carboxamide Series Leading To Highly Potent, Selective And Orally Bioavailable Syk Inhibitors
Neil GARTON (GLAXOSMITHKLINE, Stevenage, United Kingdom)
13:45
Session Chair
Didier ROGNAN (UNIVERSITÉ DE STRASBOURG, Illkirch, France)
13:50
Virtual Screening - Success Stories and Challenges
Jürgen BAJORATH (UNIVERSITY OF BONN, Bonn, Germany)
14:30
Targeting the Dynamic Nature of Protein-Protein Interfaces
Andreas BERNKOP-SCHNÜRCH (LEOPOLD-FRANZENS UNIVERSITY, Innsbruck, Austria)
13:45
Session Chair
Peter ETTMAYER (BOEHRINGER INGELHEIM, Vienna, Austria)
13:50
Discovery of Small Molecule Inhibitors of IGF-1R
Mark WITTMAN (BRISTOL-MYERS SQUIBB CO., Wallingford, United States)
14:30
Inhibitors of the MDM2-p53 Interaction
Lutz WEBER (NEXUSPHARMA, Langhorne, United States)
15:10
Discovery of a Potent and Selective SMO Inhibitor
Stefan PEUKERT (NOVARTIS, CAMBRIDGE MA, United States)
13:45
Session Chair
Gloria SERRA (UDELAR, Montevideo, Uruguay)
13:50
Antiinflammatory Drugs from Natural Products
Peter WIPF (UNIVERSITY OF PITTSBURGH, Pittsburgh, United States)
14:30
Marine Natural Products as Drug Source
Mercedes ÁLVAREZ (SCIENTIFIC PARC OF BARCELONA, Barcelona, Spain)
15:10
Antibiotic Clusters
Pal HERCZEGH (UNIVERSITY OF DEBRECEN, Debrecen, Hungary)
17. Imaging Biomarkers
18. Hot Topics in Anti-Infectives
19. Covalent Inhibitors in Drug Discovery
16:15
Session Chair
Gilles TAMAGNAN (INSTITUTE FOR NEURODEGENERATIVE DISORDERS AND MOLECULAR NEUROIMAGING, LLC, New Haven, United States)
16:20
PET Imaging in the Discovery of New Therapeutics
Terence HAMILL (MERCK RESEARCH LABORATORIES, West Point, United States)
17:00
The Next Generation of PET Cardiac Imaging Agents: Discovery of Flurpiridaz F 18 for Detection of Coronary Disease and LMI1195 for Sympathetic Neuronal Imaging
Simon ROBINSON (LANTHEUS MEDICAL IMAGING, North Billerica, United States)
17:40
PET Imaging for Oncology
Christer HALLDIN (KAROLINSKA INSTITUTET PET CENTRE, Stockholm, Sweden)
16:15
Session Chair
Lieven MEERPOEL (JOHNSON & JOHNSON PRD, Beerse, Belgium)
16:20
Advances in Bacterial Fatty Acid Synthesis Inhibitors (FAS-II)
Alan KOZIKOWSKI (UNIVERSITY OF ILLINOIS, Chicago, United States)
17:00
Benzoxaboroles as Anti-Infective Agents
Stephen BAKER (ANACOR PHARMACEUTICALS, Palo Alto, United States)
17:20
Discovery of TMC-207, a Novel Antituberculosis Agent
Jérôme GUILLEMONT (TIBOTEC, Val de Reuil, France)
17:40
HDAC Inhibitors Able to Reduce Acquired Antifungal Resistance
Antonello MAI (UNIVERSITA DEGLI STUDI DI ROMA, Roma, Italy)
16:15
Session Chair
Stan VAN BOECKEL (SCHERING-PLOUGH, Oss, The Netherlands)
16:20
Renaissance of Covalent Inhibitors
Tjeerd BARF (MERCK, Oss, The Netherlands)
17:00
Cathepsin Cystein Protease Inhibitors with Focus on Discovery of MK-0822
Cameron BLACK (MERCK FROST CENTRE FOR THERAPHEUTIC RESEARCH, Pointe-Claire-Dorval, Canada)
17:40
Targeting Drug Resistance in Protein Kinases with Irreversible Inhibitors
Daniel RAUH (CHEMICAL GENOMICS CENTRE OF THE MAX-PLANCK-SOCIETY, Dortmund, Germany)
20. Sunset Session:
Academic curriculae and industrial careers More info
How to (re)organize academic curricula to guarantee to young medicinal chemists a successful start in an industrial environment?
Henk TIMMERMAN (VU UNIVERSITY AMSTERDAM, Amsterdam, The Netherlands)
18:05
Klaus MÜLLER (F. HOFFMANN-LA ROCHE LTD, Basel, Switzerland)
18:40
Gary TRESADERN (JOHNSON & JOHNSON PHARMACEUTICAL R&D, Toledo, Spain)
18:55
Anne VALADE (UCB, Braine-l'Alleud, Belgium)
08/09/2010
08:30
The PROUS INSTITUTE-OVERTON & MEYER Award for New Technologies in Drug Discovery Lecture (R)Evolutions in Drug Discovery through Conceptual and Technological Innovations
Klaus MÜLLER (F. HOFFMANN-LA ROCHE LTD, Basel, Switzerland)
09:15
The UCB-EHRLICH AWARD for Excellence in Medicinal Chemistry Lecture New HIV Therapies: the Discovery of Maraviroc and Lersivirine
Anthony WOOD (PFIZER, Sandwich, Kent, United Kingdom)
10:00
Exhibition & Coffee
21. Process R&D and Scale-up: Chemistry, Crystals & More - Challenges and Success Stories
22. Emerging Drugs - Case Studies of Recently Disclosed New Medicines
23. The Challenges in Designing Multi-Targeted Ligands and Drugs - the Good, the Bad and the Ugly (ACS Session I)
10:30
Session Chair
Herbert STARK (SANOFI-AVENTIS, FRANKFURT/MAIN, Germany)
10:35
Scale-up of API Processes - Challenges of Solid State Properties: Case Studies
Roland THIEME (HOFFMANN-LA ROCHE, Basel, Switzerland)
11:15
Salt Selection for Scale-up and Development
Stefan BALBACH (SANOFI-AVENTIS, Frankfurt/Main, Germany)
11:55
Attrition Induced Grinding for the Synthesis of Some Commercial Drugs
Richard KELLOGG (SYNCOM, Groningen, The Netherlands)
10:30
Session Chair
Nicholas CARRUTHERS (JOHNSON & JOHNSON R&D, San Diego, United States)
10:35
Dapagliflozin, a Novel SGLT2 Inhibitor
William WASHBURN (BMS, Princeton, United States)
11:15
A Novel CHK1 Inhibitor in Advanced Clinical Trials
Timothy GUZI (SCHERING-PLOUGH RESEARCH INSTITUTE, Cambridge, United States)
11:35
TMC 435, a Novel HCV Protease Inhibitor in Advanced Clinical Trials
Pierre RABOISSON (TIBOTEC, Mechelen, Belgium)
11:55
Discovery of a Novel Orexin Receptor Antagonist for the Treatment of Sleep Disorders
Paul COLEMAN (MERCK RESEARCH LABORATORIES, West Point, United States)
10:30
Session Chair
John BUTERA
10:35
Multi-Targeted Drug Discovery: Strategies and Challenges for Medicinal Chemists
Richard MORPHY (MERCK, Lanarkshire, United Kingdom)
11:15
Dual 5-HT/NE Reuptake Inhibitors - A Pfizer Case History in the
Challenges of Multi-Pharmacology Drug Discovery
Florian WAKENHUT (PFITZER CENTRAL RESEARCH, Kent, United Kingdom)
11:55
Discovery of Potent Dual Angiotensin II and Endothelin A Receptor Antagonists
William WASHBURN (BMS, Princeton, United States)
12:00
ELSEVIER WORKSHOP
12:15
Poster Session 3 - Lunch
15:00
Excursion
20:00
Gala Dinner
09/09/2010
24. G-Protein Coupled 7TM Receptors - New Insights into their Structure and Ligand Recognition
Structural Design and Optimization of Orally Available Renin Inhibitors
David CLAREMON (VITAE PHARMACEUTICAL, Fort Washington, United States)
09:00
BGG492, a Competitive AMPA/kainate Antagonist in Clinical Development for the Treatment of Migraine and Epilepsy
Yves P. AUBERSON (NOVARTIS INSTITUTE FOR BIOMEDICAL RESEARCH, Basel, Switzerland)
09:25
Discovery of a Potent, Selective and Orally Bioavailable Acidic 11betaHydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitor
Paul WHITTAMORE (ASTRAZENECA, Macclesfield, United Kingdom)
09:50
MK-1903: a Potent Niacin Receptor (GPR109a/ HCA2) Agonist
Douglas BOATMAN (ARENA PHARMACEUTICALS, San Diego, United States)
08:30
Session Chair
David WINKLER (CSIRO MOLECULAR SCIENCE, Clayton, Australia)
08:35
Protein-Protein Interactions and Apoptosis in Cancer Cells
John FLYGARE (STANFORD UNIVERSITY, Stanford, United States)
09:15
Small molecule inhibitors of the neuropilin-1 VEGF-A interaction
Ashley JARVIS (DOMAINEX LTD, Cambridge, United Kingdom)
09:55
Targeting Pdz Domains: From Computational Library Design, To Nmr And X-Ray, To In Vivo Studies
Dmytro KOVALSKYY (KIEV NATIONAL UNIVERSITY, KIEV, Ukraine)
10:15
Exhibition & Coffee
27. Finding the Right Binding Pockets: Allosteric Modulators of G-Protein Coupled Receptors for Non-CNS Diseases(ACS Session II)
28. Recent Case Studies in DD and Development
29. New Medicines Beyond Small Molecules - Novel Biologics
10:45
Session Chair
Robert A. FECIK (UNIVERSITY OF MINNESOTA, Minneapolis, United States)
10:50
The Discovery of Maraviroc, an Allosteric CCR5 Antagonist for HIV Infection
Patrick DORR (SURREY UNIVERSITY, Surrey, United Kingdom)
11:30
Allosteric, Small Molecule Agonists of the GLP-1 Receptor for Diabetes
Lotte KNUDSEN (NOVO-NORDISK, Bagsværd, Denmark)
12:10
Follicle Stimulating Hormone Receptor Negative Allosteric Modulators (Fshr Nam): Discovery And Development Of A New Series Of Orally Bioavailable Dimethoxy-Benzamides
.jpg){kind=small}
